Department of Food Science and Nutrition, Pavillon Paul-Comtois, Université Laval, Québec, Québec, Canada.
Institute of Nutrition and Functional Foods, Université Laval, Québec, Québec, Canada.
PLoS One. 2021 Sep 23;16(9):e0257466. doi: 10.1371/journal.pone.0257466. eCollection 2021.
Celiac disease (CD) is triggered by ingestion of gluten-containing cereals such as wheat, barley, rye and in some cases oat. The only way for affected individuals to avoid symptoms of this condition is to adopt a gluten-free diet. Thus, gluten-free foodstuffs need to be monitored in order to ensure their innocuity. For this purpose, commercial immunoassays based on recognition of defined linear gluten sequences are currently used. These immunoassays are designed to detect or quantify total gluten regardless of the cereal, and often result in over or underestimation of the exact gluten content. In addition, Canadian regulations require a declaration of the source of gluten on the label of prepackaged foods, which cannot be done due to the limitations of existing methods. In this study, the development of new antibodies targeting discrimination of gluten sources was conducted using synthetic peptides as immunization strategy. Fourteen synthetic peptides selected from unique linear amino acid sequences of gluten were bioconjugated to Concholepas concholepas hemocyanin (CCH) as protein carrier, to elicit antibodies in rabbit. The resulting polyclonal antibodies (pAbs) successfully discriminated wheat, barley and oat prolamins during indirect ELISA assessments. pAbs raised against rye synthetic peptides cross-reacted evenly with wheat and rye prolamins but could still be useful to successfully discriminate gluten sources in combination with the other pAbs. Discrimination of gluten sources can be further refined and enhanced by raising monoclonal antibodies using a similar immunization strategy. A methodology capable of discriminating gluten sources, such as the one proposed in this study, could facilitate compliance with Canadian regulations on this matter. This type of discrimination could also complement current immunoassays by settling the issue of over and underestimation of gluten content, thus improving the safety of food intended to CD and wheat-allergic patients.
乳糜泻(CD)是由摄入含麸质的谷物(如小麦、大麦、黑麦,在某些情况下还有燕麦)引起的。受影响个体避免该病症症状的唯一方法是采用无麸质饮食。因此,需要对无麸质食品进行监测,以确保其无害。为此,目前使用基于识别定义线性麸质序列的商业免疫测定法。这些免疫测定法旨在检测或定量总麸质,而不管谷物如何,并且通常会导致对确切麸质含量的高估或低估。此外,加拿大法规要求在预包装食品的标签上声明麸质的来源,但由于现有方法的限制,这无法做到。在这项研究中,使用合成肽作为免疫策略,针对麸质来源的区分开发了新的抗体。从麸质的独特线性氨基酸序列中选择了 14 个合成肽,与 Concholepas concholepas 血蓝蛋白(CCH)偶联作为蛋白载体,在兔子中引发抗体。由此产生的多克隆抗体(pAb)在间接 ELISA 评估中成功区分了小麦、大麦和燕麦醇溶蛋白。针对黑麦合成肽产生的 pAb 与小麦和黑麦醇溶蛋白均匀交叉反应,但与其他 pAb 结合仍可用于成功区分麸质来源。使用类似的免疫策略,通过产生单克隆抗体,可以进一步细化和增强对麸质来源的区分。这种能够区分麸质来源的方法,例如本研究中提出的方法,可以促进加拿大在这方面法规的遵守。这种区分也可以补充当前的免疫测定法,解决对麸质含量的高估和低估问题,从而提高针对 CD 和小麦过敏患者的食品安全性。